Nexalis Therapeutics Loss Widens as Net Tangible Assets Slide Further

InhaleRx Limited ( (AU:NX1) ) just unveiled an update.

Nexalis Therapeutics Ltd has reported a significant widening of its annual loss, with the deficit after tax for the year to 31 December 2025 rising 51.3% to $1.83 million, compared with $1.21 million a year earlier. The company’s net tangible assets per share deteriorated sharply from negative 0.03 cents to negative 0.49 cents, and it again did not declare any dividends, underscoring the ongoing funding and capital pressures typical of early-stage biotech developers.

Management flagged that the preliminary financial report for 2025 remains unaudited at this stage, which means the figures may be subject to change before final sign-off. With no gains or losses of control over subsidiaries and no associate or joint venture interests reported, the results highlight that Nexalis’s financial performance is driven primarily by its core development activities rather than corporate transactions, a factor current and prospective investors will weigh against the company’s longer-term prospects.

The most recent analyst rating on (AU:NX1) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on InhaleRx Limited stock, see the AU:NX1 Stock Forecast page.

More about InhaleRx Limited

Nexalis Therapeutics Ltd, formerly known as InhaleRx Limited, operates in the biotechnology and therapeutics sector. The company is focused on developing pharmaceutical treatments, with activities that generate research and development expenses but no current dividend distributions, reflecting its status as a pre-revenue or early-stage clinical business.

Average Trading Volume: 268,402

Technical Sentiment Signal: Sell

Current Market Cap: A$7.09M

Learn more about NX1 stock on TipRanks’ Stock Analysis page.